Trandolapril/Verapamil: Tark

CSR Synopses following approval of a new medicine or a new indication for an approved medicine in the US or EU. We are making CSR synopses available to supplement the public information available to patients and healthcare providers about the results of our clinical trials and the evidence used to approve a new medicine or a new indication.

{m} Entries

Phase
Study Indication or Disease
Study Name
M03-599 AbbVie_IU_icons_outlined_v3 Hypertension Phase 4 A Phase 4, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypertensive, Type 2 Diabetic Subjects with Diabetic Nephropathy
M03-598 AbbVie_IU_icons_outlined_v3 Hypertension Phase 4 A Phase IV, Randomized, Open-Label, Active controlled Study to Compare the Effects of Tarka and Hyzaar on Glucose Tolerance in Subjects with Metabolic Syndrome. (STAR)
M03-598 AbbVie_IU_icons_outlined_v3 Hypertension CSR.ORG A Phase IV, Randomized, Open-Label, Active controlled Study to Compare the Effects of Tarka and Hyzaar on Glucose Tolerance in S More»
M03-599 AbbVie_IU_icons_outlined_v3 Hypertension CSR.ORG A Phase 4, Randomized, Open-Label, Active Controlled Study to Compare the Effects of Tarka® and Lotrel® on Albuminuria in Hypert More»
CANA‑03‑003  AbbVie_IU_icons_outlined_v3 Hypertension Phase 4 Protocol No. CANA-03-003: A Prospective, Open-Label Study to Evaluate the Effect of an Escalating Dose Regimen of Trandolapril on Blood Pressure in Treatment-Naive and Concurrently Treated Hypertensive Patients (TRAIL)